AI and Healthcare: Roche, Avant Technologies, and Ainnova Partner to Combat Diabetic Retinopathy

The Intersection of AI, Medicine, and Stocks: A New Era of Opportunities Issued on behalf of Avant Technologies Inc. - Avant Technologies (OTC:AVAI), Amazon.com (NASDAQ:AMZN)

VANCOUVER, BC, Dec. 4, 2024 /PRNewswire/ -- USA News Group News Commentary - Artificial intelligence (AI) is revolutionizing healthcare, offering solutions that could dramatically reduce deficits in the U.S. healthcare system. The U.S. Food and Drug Administration (FDA) is already shifting its focus toward the possibilities of Generative AI (GenAI), having recently presented a detailed 30-page report to its committee members outlining the technology's potential. Capable of processing and synthesizing vast amounts of data with unparalleled speed, GenAI is emerging as a transformative force in healthcare innovation. From accelerating drug discovery to refining diagnostics and monitoring treatments, AI advancements are driving rapid progress, fueled by the efforts of companies like Avant Technologies, Inc. AVAI, Roche Holding AG RHHBY RHHVF)), Amazon.com, Inc. AMZN, Spectral AI, Inc. MDAI, Medtronic plc MDT, and GE HealthCare Technologies Inc. GEHC. The article continued: Driving this AI transformation is a booming $9.58 billion market for AI Training Datasets. According to MarketsandMarkets Research, the global AI in Precision Medicine Market is forecast to reach US$3.92 billion by 2030, growing at a staggering 30.7% compound annual growth rate (CAGR). Additionally, the Healthcare IT Market is on track to hit US$834.35 billion by 2029, with a projected 14.7% CAGR, as AI continues to enhance system interoperability and revolutionize patient care. Avant Technologies' Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy Avant Technologies, Inc. AVAI, an emerging technology company developing solutions in artificial intelligence in healthcare, today announced it has entered into a strategic alliance with global biotech giant Roche Holding AG RHHBY RHHVF)), and leading pre-paid health plan provider Salud 360, to begin a pilot program to combat diabetic retinopathy using cutting-edge technology from Avant's partner Ainnova Tech, a leading healthcare technology company focused on revolutionizing early disease detection using AI. Roche, Ainnova, and Salud 360 signed a strategic alliance to improve access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy using Ainnova's advanced technology and a patient-centered approach. The pilot program will initially be implemented in Costa Rica where diabetes affects about 10.4% of the adult population. If successful, Avant and Ainnova hope to implement a similar program in the United States, Canada, and Europe through Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova. "At Roche, we are committed to timely diagnosis of diseases to improve clinical outcomes and thus contribute to the sustainability of the healthcare system," said, Alvaro Soto, General Manager of Roche Central America, Caribbean, and Venezuela. "By leveraging technology, we seek to improve lives, optimize diagnoses, and ensure that every patient has access to timely and effective treatment. With this model, we not only seek to address the problem of diabetic retinopathy, but also to establish a replicable path for other diseases that require innovative solutions." The pilot program will use non-mydriatic fundus cameras and artificial intelligence -- developed by Ainnova Tech -- to automatically analyze retinal images and identify microscopic changes in the retina. Such changes would be an early indicator of diabetic retinopathy without the need for invasive tests. By implementing the pilot program in Costa Rica, this strategic alliance can take advantage of the country's robust healthcare system and its focus on technological innovation. Patients who are members of Salud 360 will be the first to benefit from screenings at affiliated clinics. Those at risk will be referred immediately to ophthalmology specialists, guaranteeing comprehensive and timely care. The results of this pilot program will be the basis for developing the model beyond borders to benefit communities facing similar challenges in accessing medical care. "We are proud to be able to put our technology at the service of a project that has the potential to prove itself as a massive impact model in early detection, and which we believe is replicable globally," said Vinicio Vargas, CEO of Ainnova Tech and member of AAC's Board of Directors. "Today, we are starting with diabetic retinopathy, but the vision is that we can eventually multiply this same effort for other critical diseases that require innovative solutions." According to data from the Costa Rican Institute for Research and Teaching in Nutrition and Health (Inciensa), uncontrolled diabetes is the leading cause of preventable blindness in the country's adult population. To make matters worse, between 20% and 40% of diabetic patients develop diabetic retinopathy, a silent but devastating condition if not detected and treated in time. According to the World Health Organization, 80% of cases of blindness due to diabetes are preventable with early and effective interventions. Therefore, early detection is crucial and technological innovation can help make a huge difference. CONTINUED... Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ Other recent industry developments and happenings in the market include: Amazon.com, Inc. AMZN, through its AWS re:Invent -- Amazon Web Services (AWS) subsidiary, recently announced that LG AI Research, the artificial intelligence (AI) research hub of South Korean conglomerate LG Group, has used the world's leading cloud to develop its new pathology foundation model (FM) for earlier cancer diagnosis and treatment. The histopathology image-specific model, EXAONEPath, analyzes tissue sample images from cancer patients in under a minute, cutting genetic testing times from two weeks, helping doctors deliver faster and more effective treatments. "The healthcare industry is making rapid progress in its use of AI on AWS to accelerate diagnoses and get patients into treatment faster," said Dan Sheeran, general manager, Healthcare and Life Sciences at AWS. "Using AWS, LG AI Research can develop and use EXAONEPath at an unprecedented scale, reducing data processing and model training times and improving accuracy. This will allow healthcare providers to improve cancer diagnoses and treatments, reduce wait times, and personalize patient care." EXAONEPath delivers 86.1% accuracy in detecting cancer-related cellular features, matching top pathology models while significantly reducing training time with AWS -- from 60 days to one week. By leveraging Amazon SageMaker and advanced AWS services, LG AI Research processed 285 million data points and over 35,000 high-resolution tissue images in just eight months, cutting costs by 35% and data preparation time by 95% for faster, more efficient cancer detection. Spectral AI, Inc. MDAI, an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, recently announced the successful completion of truthing for all images gathered from burn centers across the USA. This milestone represents a pivotal step in training Spectral's proprietary DeepView® System to predict wound healing outcomes accurately. Having completed the process for burn centers, Spectral AI is now initiating truthing for images collected from emergency departments and emergency rooms nationwide, expanding the scope of the DeepView® System's capabilities. Truthing is the process of collecting verified data on wound healing to train AI algorithms. By combining early treatment images with biopsies, assessments, and expert evaluations, the DeepView® System can predict which wounds will heal naturally and which need intervention. "By completing the truthing process for burn centers, this adds to Spectral AI's largest comprehensive tissue dataset, encompassing over 3,000 biopsied images," said Dr. J. Michael DiMaio, Chairman of Spectral AI's Board of Directors. "This achievement reflects collaboration between internationally recognized burn experts, skilled dermatopathologists, and our dedicated engineers and data scientists. This multidisciplinary effort ensures that our technology evolves with precision and reliability, surpassing the limitations of traditional diagnostic methods." Medtronic plc MDT, a global leader in healthcare technology, recently announced U.S. Food and Drug Administration (FDA) clearance for its new InPen™ app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera™ continuous glucose monitor (CGM). Medtronic's Smart MDI system combines its InPen™ smart insulin pen with its newest Simplera™ CGM -- its first disposable, all-in-one CGM that's half the size of previous Medtronic CGMs. "This is a significant leap forward for those on multiple daily injections, offering intelligent dosing insights and simplifying diabetes management," said Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP. "By reducing the guesswork out of insulin dosing, this tool helps maintain stable blood sugars, optimize long-term health, and reduce complications from hyperglycemia." As per the release, Medtronic will initiate a limited market release beginning with existing standalone CGM and InPen™ customers followed by a broad commercial launch. Medtronic has pioneered its first-of-its-kind innovations for over 40 years, designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI. GE HealthCare Technologies Inc. GEHC, a leader in digital solutions used in the diagnosis, treatment, and monitoring of patients, recently exhibited more than 40 innovations at the Radiological Society of North America's (RSNA) 2024 Annual Meeting, including several key artificial intelligence (AI)-enabled technologies to optimize patient care and increase operational efficiencies. "GE HealthCare is on a mission to deliver technologies that address radiologists' biggest areas of concern," said Peter Arduini, CEO of GE HealthCare. "We are innovating new solutions using the latest AI and digital technologies at the device, care pathway, and enterprise-level, helping clinicians deliver a more personal, precise, and human approach to care from diagnosis to treatment to recovery." Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ CONTACT: USA NEWS GROUP [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time hereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content:https://www.prnewswire.com/news-releases/the-intersection-of-ai-medicine-and-stocks-a-new-era-of-opportunities-issued-on-behalf-of-avant-technologies-inc-302322216.html SOURCE USA News Group Market News and Data brought to you by Benzinga APIs

Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That's Expected to be a $7.2 Billion Market by 2029 By Investing.com

PALM BEACH, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The use of Artificial Intelligence (AI) in the diagnostics market has transformed medical diagnosis and therapy. AI algorithms and machine learning approaches have shown impressive skills in analyzing massive volumes of medical data and producing significant insights for accurate and efficient diagnosis. Artificial intelligence-driven diagnosis is promoting significant development in the medical sector, from radiology and pathology to cardiology and cancer diagnosis. With the enhanced skills of practitioners using AI-enabled technologies, diagnostic accuracies increase, saving valuable time. In addition, these AI systems can learn from real-world data and improve over time, therefore proving to be very good companions for healthcare practitioners. The AI in diagnostics market growth has enormous promise for revolutionizing healthcare delivery by offering faster, more accurate diagnoses, improving patient outcomes, and saving lives. A report from ResearchAndMarkets said that the AI in diagnostics market is expected to grow at a CAGR of 33.47%, reaching a market size of US$7.268 billion in 2029 from US$1.716 billion in 2024. Active companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Roche (LON:0QQ6) (OTCQX: RHHBY (OTC:RHHBY)), Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), Tempus AI, Inc. (NASDAQ: TEM), Intuitive (NASDAQ: ISRG). The ResearchAndMarkets report said: Machine learning and deep learning algorithms have significantly contributed to the expansion of AI in the diagnostics business. These algorithms have shown an extraordinary ability to handle and analyze massive volumes of medical data, allowing for precise and rapid diagnosis. According to a report published by WHO, a deep learning system detected skin cancer with an accuracy of 94.5%, outperforming human dermatologists. Furthermore, according to a study published in the Journal of the American Medical (TASE:PMCN) Association, an AI system properly recognized breast cancer in mammograms with a sensitivity of 94.5%. These developments demonstrate the power of machine learning and deep learning algorithms in improving diagnostic accuracy and patient outcomes. North America is the Market Leader in the AI Diagnostics Market. North America holds a significant share of the AI Diagnostics market. This can be linked to factors such as a strong healthcare infrastructure, new technologies, and a favorable regulatory environment. Several significant players in the AI business, including prominent healthcare facilities and research organizations, are located in the region. Furthermore, North America has seen major expenditures in AI research and development, which has fueled the expansion of AI in the diagnostics market. North America continues to employ AI for diagnostic purposes, thanks to an emphasis on innovation and technical developments. Avant Technologies, Inc. (OTCQB: AVAI) Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy- Avant Technologies, Inc. (Avant or the Company), partner, Ainnova Tech, Inc., (Ainnova) a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the company has entered into a strategic alliance with global biotech, Roche, and leading pre-paid health plan provider, Salud 360, to begin a pilot program to combat diabetic retinopathy using Ainnova's cutting-edge technology. The pilot program will initially be implemented in Costa Rica where diabetes affects about 10.4% of the adult population. If successful, Avant and Ainnova hope to implement a similar program in the United States, Canada, and Europe through Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova. According to data from the Costa Rican Institute for Research and Teaching in Nutrition and Health (Inciensa), uncontrolled diabetes is the leading cause of preventable blindness in the country's adult population. To make matters worse, between 20% and 40% of diabetic patients develop diabetic retinopathy, a silent but devastating condition if not detected and treated in time. According to the World Health Organization, 80% of cases of blindness due to diabetes are preventable with early and effective interventions. Therefore, early detection is crucial and technological innovation can help make a huge difference. Roche, Ainnova, and Salud 360 signed a strategic alliance to improve access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy using Ainnova's advanced technology and a patient-centered approach. The pilot program will use non-mydriatic fundus cameras and artificial intelligence"developed by Ainnova Tech"to automatically analyze retinal images and identify microscopic changes in the retina. Such changes would be an early indicator of diabetic retinopathy without the need for invasive tests. At Roche, we are committed to timely diagnosis of diseases to improve clinical outcomes and thus contribute to the sustainability of the healthcare system. By leveraging technology, we seek to improve lives, optimize diagnoses, and ensure that every patient has access to timely and effective treatment. With this model, we not only seek to address the problem of diabetic retinopathy, but also to establish a replicable path for other diseases that require innovative solutions, said, Alvaro Soto, General Manager of Roche Central America, Caribbean, and Venezuela. By implementing the pilot program in Costa Rica, this strategic alliance can take advantage of the country's robust healthcare system and its focus on technological innovation. Patients who are members of Salud 360 will be the first to benefit from screenings at affiliated clinics. Those at risk will be referred immediately to ophthalmology specialists, guaranteeing comprehensive and timely care. The results of this pilot program will be the basis for developing the model beyond our borders to benefit communities facing similar challenges in accessing medical care. Vinicio Vargas, Chief Executive Officer of Ainnova Tech and member of AAC's Board of Directors, emphasized, We are proud to be able to put our technology at the service of a project that has the potential to prove itself as a massive impact model in early detection, and which we believe is replicable globally. Today, we are starting with diabetic retinopathy, but the vision is that we can eventually multiply this same effort for other critical diseases that require innovative solutions. CONTINUED| Read this and more news for Avant Technologies at: https://www.financialnewsmedia.com/news-avai/ In other healthcare/technology industry developments and happenings in the market recently include: Roche (OTCQX: RHHBY) recently announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (PSTX), a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies. Based in San Diego, California, Poseida's R&D portfolio includes pre-clinical and clinical-stage off-the-shelf (also referred to as allogeneic) CAR-T therapies across several therapeutic areas including haematological malignancies, solid tumours, and autoimmune disease, as well as manufacturing capabilities and technology platforms. The acquisition builds on the existing partnership between Roche and Poseida following the collaboration and licence agreement established in 2022, which focuses on developing off-the-shelf CAR-T cell therapies to address medical needs of patients with haematological malignancies. The business combination of two AI-powered drug discovery and development companies, Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) and Exscientia has recently been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform. Exscientia ADSs (EXAI) ceased trading and will be delisted from Nasdaq. I believe the combination of the incredible teams and platforms at Exscientia and Recursion position us as the leader of the AI-enabled drug discovery and development space, said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. With more than 10 clinical and preclinical programs in the internal pipeline, more than 10 partnered programs and over $450M in upfront and realized milestone payments received from partners to date out of more than $20B possible, we are advancing a flywheel of discovery and creating value in our pipeline through technology. Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology, to integrate its comprehensive genomic testing directly into Flatiron's cloud-based Electronic Medical Record (EMR) platform, OncoEMR ® through the Molecular Profiling Integration (MPI). This integration will provide oncologists with seamless access to Tempus' suite of testing options, enhancing their ability to deliver personalized cancer care. Flatiron's MPI"a two-way integration between laboratories and OncoEMR"will allow the 4,200 providers at more than 800 community-based cancer care locations across the U.S. in Flatiron's network to order and receive results from Tempus directly in the OncoEMR workflow. The integration will enable electronic ordering, order tracking, and the receipt of Tempus test results directly within the OncoEMR platform, significantly reducing administrative burden and improving the experience for care providers. Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced this year that the U.S. Food and Drug Administration (FDA) cleared a labeling revision for da Vinci (EPA:SGEF) X and Xi specific to radical prostatectomy. This clearance was based on real-world evidence ( RWE (LON:0HA0)) collected from 2007 to 2014 that demonstrates overall five- to 10-year survival following robotic-assisted radical prostatectomy is similar to non-robotic radical prostatectomy. In a public-private collaboration, Intuitive worked with the FDA, healthcare analytics company Aetion, and the National Evaluation System for health Technology (NEST), utilizing its NEST Mark process to support the validity of the real-world data used in the labeling revision submission. This project demonstrated the utility of this type of collaboration in generating high-quality RWE to support marketing applications to the FDA and could allow for similar comprehensive long-term survival assessments for other cancer procedures, which helps advance regulatory science. About FN Media Group: At FN Media Group, via our top-rated online news portal at www.financialnewsmedia.com, we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today's emerging companies. #tickertagpressreleases #pressreleases Follow us on Facebook (NASDAQ:META) to receive the latest news updates: https://www.facebook.com/financialnewsmedia Follow us on Twitter for real time Market News: https://twitter.com/FNMgroup Follow us on Linkedin: https://www.linkedin.com/in/financialnewsmedia/ DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated forty nine hundred dollars for news coverage of the current press releases issued by Avant Technologies, Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements. Contact Information: Media Contact email: [email protected] - +1(561)325-8757